Cipla launches ‘inhaled insulin’, a needle-free alternative for people with diabetes

Core Viewpoint - Cipla has launched Afrezza, a rapid-acting inhaled insulin, in India, providing a needle-free alternative to traditional injectable insulin therapy [1][2]. Product Details - Afrezza is an inhalation powder that dissolves quickly upon oral inhalation, beginning to lower blood glucose levels within approximately 12 minutes, mimicking the body's natural insulin response [2]. - The product will be available in single-use cartridges and delivered through an inhaler device, making the process of inhaling insulin straightforward [3]. Target Audience and Benefits - The inhaled insulin is designed for adults with type-1 and type-2 diabetes mellitus, aiming to improve adherence to therapy and enable quicker glycemic control [5]. - It addresses emotional and practical barriers that often lead patients to delay or discontinue insulin therapy [5]. Health Considerations - The product is not advisable for individuals with pulmonary concerns such as asthma or chronic obstructive pulmonary disease (COPD) [4].